LINEZOLID 600mg. IP

The first member of a new generation of antibiotics, the synthetic oxazolidinones, approved for the treatment of Gram-positive bacterial infections, including resistant strains. (Andrzej Jankowski, 2006) Plays an important role in the management of serious gram-positive infections including methicillin-resistant staphylococci, penicillin-resistant pneumococci, and vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. (C M Perry, 2001) Acts as a bacteriostatic against some species (e.g., enterococci) and bactericidal against others (e.g., pneumococci). (R Norrby, 2001) As effective as clarithromycin 250mg or cefpodoxime proxetil 200mg in the treatment of patients with uncomplicated skin and soft tissue infections or community-acquired pneumonia.(C M Perry B. J., 2001) An effective therapy as intravenous vancomycin 1 g in the treatment of patients with hospital-acquired pneumonia and those with infections caused by methicillin-resistant staphylococci. (D Clemett, 2000) A valid therapeutic option for treating both community and hospital-acquired infections due to multiresistant Gram-positive cocci. (G Corti, 2000) A safe and effective treatment for adult liver transplant patients with gram-positive bacterial infections. (S Radunz, 2011) A promising drug for the treatment of prosthetic joint infections due to methicillin-resistant Staphylococcus aureus or other Gram-positive pathogens, especially a long-term antibiotic therapy is required. (M Bassetti, 2001) Superior clinical cure rates for the treatment of skin and soft tissue infections 88.1 % with linezolid and 86.1 % with penicillinase-stable penicillins. (W A Krueger, 2002) Has similar safety and efficacy to teicoplanin in treating Gram-positive infections in critically ill patients. (Jorge A Cepeda, 2004) More effective than glycopeptides, macrolides, and beta-lactams for skin and soft tissue infections. (Matthew E Falagas, 2008)